|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The incorporation of L-asparaginase and pegylated asparaginase into pediatric-inspired regimens has conferred a survival advantage in treatment of adults with acute lymphoblastic leukemia.
|
30917738 |
2020 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Discontinuation of L-asparaginase and poor response to prednisolone are associated with poor outcome of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia.
|
30689137 |
2019 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Most patients had secondary causes such as uncontrolled diabetes mellitus (30%), L-asparaginase and high-dose corticosteroid therapy for acute lymphoblastic leukemia (28%), and sirolimus/tacrolimus therapy after solid organ transplantation (14%).
|
29454679 |
2019 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of the study was to determine the level of IgM, IgG and IgE-class anti-L-asp antibodies during the induction and reinduction phases of acute lymphoblastic leukemia therapy and their influence on L-asp activity.
|
30826572 |
2019 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Due to this mechanism of action observed, L-asparaginase is widely used in the treatment of Acute Lymphoblastic Leukemia, since these cells use asparagine for their survival.
|
30762133 |
2019 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Experience with generic pegylated L-asparaginase in children with acute lymphoblastic leukemia and monitoring of serum asparaginase activity.
|
30488741 |
2019 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
L-asparaginase (ASNase) serves as an effective drug for adolescent acute lymphoblastic leukemia.
|
31523835 |
2019 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
l-asparaginase (E.C.3.5.1.1), an anti-cancer drug has been used in the treatment of acute lymphoblastic leukemia.
|
29079538 |
2018 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Acute central nervous system complications and ammonium levels in adult patients with acute lymphoblastic leukemia receiving l-asparaginase.
|
28728499 |
2018 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
For over four decades l. asparaginase utic agent for the treatment of a variety of lymphoproliferative disorders and lymphoma such as acute lymphoblastic leukemia.
|
28851634 |
2018 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
L-asparaginase is a potential therapeutic enzyme widely used in the chemotherapy protocols of pediatric and adult patients with acute lymphoblastic leukemia.
|
30139388 |
2018 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficacy and safety of G-CSF, low-dose cytarabine and aclarubicin in combination with l-asparaginase, prednisone in the treatment of refractory or relapsed acute lymphoblastic leukemia.
|
28982056 |
2017 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In 2006, FDA has already approved the use of L-asparaginase in the treatment of acute lymphoblastic leukemia.
|
27813440 |
2017 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
l-asparaginase (l-asparagine amino hydrolase, E.C.3.5.1.1) is an enzyme clinically accepted as an antitumor agent to treat acute lymphoblastic leukemia and lymphosarcoma.
|
26694875 |
2017 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
L-asparaginase is an enzyme used as a chemotherapeutic agent, mainly for treating acute lymphoblastic leukemia.
|
27253887 |
2016 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
L-asparaginase is an integral component of therapy for acute lymphoblastic leukemia.
|
26928249 |
2016 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
E.coli type II L-asparaginase is widely used for treatment of acute lymphoblastic leukemia.
|
26867931 |
2016 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
l-asparaginase is an effective antineoplastic agent used in chemotherapy of acute lymphoblastic leukemia.
|
25697915 |
2015 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among the antitumor drugs, bacterial enzyme L-asparaginase has been employed as the most effective chemotherapeutic agent in pediatric oncotherapy especially for acute lymphoblastic leukemia.
|
26180806 |
2015 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
l-asparaginase (L-asp), a bacterial enzyme that depletes extracellular asparagine, is used to treat acute lymphoblastic leukemia in humans and a variety of aggressive lymphoid malignancies in dogs.
|
24033105 |
2014 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
L-Asparaginase (L-ASP) is a key component of therapy for acute lymphoblastic leukemia.
|
24659632 |
2014 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, our findings suggest that curcumin potentiates the antitumor effects of L-ASP in acute lymphoblastic leukemia by constitutively inhibiting AKT and AKT-regulated gene products.
|
22185211 |
2012 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In silico engineering of L-asparaginase to have reduced glutaminase side activity for effective treatment of acute lymphoblastic leukemia.
|
22042278 |
2011 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although patients with MLL-rearranged acute lymphoblastic leukemia are highly resistant to prednisolone and L-asparaginase, this resistance was not attributed to miR-196b expression.
|
20494936 |
2010 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia.
|
15665306 |
2005 |